Serotonin syndrome is caused by excessive dopamine release in the nigrostriatal pathway triggered by the combination of venlafaxine and tramadol

Producing a clinical presentation that is pharmacologically identical to neuroleptic malignant syndrome. The clonus and hyperreflexia result from dopamine-mediated excitation of the extrapyramidal motor system, while the hyperthermia reflects dopaminergic disruption of hypothalamic temperature regulation centers. Both conditions share identical underlying pathophysiology involving dopamine D2 receptor overstimulation and therefore require the same pharmacological management. The distinguishing feature is the precipitating medication class rather than any mechanistic difference. Serotonin syndrome and neuroleptic malignant syndrome are distinct conditions with different pathophysiology.

The clinical presentation results from tramadol's antagonism of venlafaxine at postsynaptic serotonin receptors

Creating a sudden serotonin withdrawal state similar to SSRI discontinuation syndrome but significantly more severe due to rapid competitive receptor displacement. Tramadol competitively displaces venlafaxine from postsynaptic 5-HT receptors, abruptly reducing serotonergic neurotransmission and triggering a rebound neurological response. The clonus and hyperreflexia represent neuronal hyperexcitability from acute serotonin depletion, analogous to the brain zaps reported during SSRI discontinuation. Hyperthermia results from loss of serotonergic thermoregulatory tone in the hypothalamus. Serotonin syndrome is a state of serotonin excess, not serotonin withdrawal or depletion.

Serotonin syndrome occurs when tramadol activates histamine H1 receptors throughout the central nervous system

Producing a severe allergic-type neurological reaction that is potentiated by the concurrent presence of venlafaxine in serotonergic synapses. The histamine-mediated mechanism explains the hyperthermia as a form of drug fever, the mydriasis as a parasympathetic histamine response, and the agitation as histaminergic cortical excitation. The clonus and hyperreflexia reflect histamine-induced excitability at the neuromuscular junction, similar to the mechanism seen in anaphylaxis-related neurological complications. This explains why cyproheptadine, an antihistamine, is used as treatment for serotonin syndrome. Serotonin syndrome is not a histamine-mediated allergic reaction. It is caused by excessive serotonin activity at 5-HT1A and 5-HT2A receptors.

Serotonin syndrome results from excessive stimulation of peripheral and central serotonin receptors, primarily 5-HT1A and 5-HT2A, due to supratherapeutic serotonergic activity from combined pharmacological mechanisms that increase synaptic serotonin

Venlafaxine inhibits serotonin reuptake while tramadol also inhibits serotonin reuptake and may enhance presynaptic serotonin release, producing additive serotonergic excess at postsynaptic receptors. The neuromuscular findings of clonus and hyperreflexia are mediated predominantly by 5-HT1A receptor overstimulation in spinal cord motor neurons. Autonomic instability and hyperthermia reflect 5-HT2A-mediated disruption of thermoregulation and peripheral sympathetic activation. This accurately describes serotonin syndrome pathophysiology. The condition results from excessive serotonergic activity at 5-HT1A and 5-HT2A receptors. Venlafaxine (SNRI) combined with tramadol (which also inhibits serotonin reuptake and has serotonin-releasing properties) creates dangerous serotonin excess.